Rise in prevalence of acute and chronic disorders, increase in the geriatric population, and increase in initiatives for awareness and education for use of suppositories drive the growth of the ...

Now, the company is looking to parse its success into a New Drug Application (NDA ... "Cristcot‘s Phase III ulcerative colitis suppository trial meets endpoints" was originally created and ...